Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid TumorsPancreatic CarcinomaOvarian CancerCervical Cancers
Interventions
DRUG

XNW28012

Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.

Trial Locations (24)

Unknown

RECRUITING

Second Affiliated Hospital of Anhui Medical University, Hefei

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Fujian Provincial Cancer Hospital, Fuzhou

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

RECRUITING

Affiliated Hospital of Guizhou Medical University, Guiyang

RECRUITING

Affiliated Hospital of Hebei University, Baoding

RECRUITING

Affiliated Cancer Hospital of Harbin Medical University, Harbin

RECRUITING

First Affiliated Hospital of Henan University of Science and Technology, Luoyang

RECRUITING

Hubei Cancer Hospital, Wuhan

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

The Second Xiangya Hospital Of Central South University, Changsha

RECRUITING

First Affiliated Hospital of Gannan Medical College, Ganzhou

RECRUITING

First Affiliated Hospital of Kunming Medical University, Yunnan

RECRUITING

Affiliated Hospital of Binzhou Medical College, Binzhou

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Linyi Cancer Hospital, Linyi

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

Sichuan Provincial People's Hospital, Chengdu

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

Yunnan Cancer Hospital, Kunming

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY